By Fineline Cube Eli Lilly (NYSE: LLY) has completed the separate purchases of US compatriots Sigilon Therapeutics (NASDAQ: SGTX) and Versanis Bio, as previously announced. The acquisitions are part of Lilly’s strategic expansion into innovative therapies for acute and chronic diseases.
Sigilon Therapeutics: Advancing Encapsulated Cell Therapies
Lilly was attracted to Sigilon’s encapsulated cell therapies, which are designed as functional cures for acute and chronic diseases. Particularly noteworthy is SIG-002, an islet cell therapy that senses blood glucose levels and releases insulin accordingly. This therapy has the potential to bypass the need for regular insulin administration, offering a significant advancement in diabetes care.
Versanis Bio: Strengthening Cardiometabolic Disease Portfolio
On the other hand, Versanis Bio’s portfolio focuses on cardiometabolic diseases, featuring myostatin antagonist bimagrumab, a weight-loss candidate drug. Lilly intends to pair bimagrumab with incretins such as tirzepatide due to its potential to improve their efficacy while preserving muscle mass. This acquisition strengthens Lilly’s position in the cardiometabolic disease space.
Recent Acquisition of Dice Therapeutics
The announcement of these acquisitions comes a week after Lilly completed the acquisition of immunology expert Dice Therapeutics (NASDAQ: DICE). These strategic moves demonstrate Lilly’s commitment to expanding its therapeutic offerings and investing in innovative solutions across various disease areas.-Fineline Info & Tech